NR1H4 and metabolic dysfunction-associated steatohepatitis: This finding suggests that FXR activators such as OCA could be employed in the treatment of NASH-related disorders, even in the later stages, as a preventative measure to prevent the progression to HCC.[32] Although there are currently no clinical trials exploring this possibility, the potential therapeutic role of FXR activators warrants further research.